Evidence map›Paper›PMID 26564224›Full record

ArticleInternational urogynecology journal2016

Effect of norfloxacin therapy for acute, uncomplicated lower urinary tract infection on vaginal Candida prevalence.

Rodrigo M Rocha, Pâmela C M Delvas Zanni, Patrícia de Souza Bonfim-Mendonça, Fabrícia Gimenes, Silvia S Dantas Alczuk, Terezinha I Estivalet Svidzinski, Márcia E Lopes Consolaro

Abstract read
PubMed Publisher
In one paragraph

Article in International urogynecology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rodrigo M RochaClinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
Pâmela C M Delvas ZanniClinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
Patrícia de Souza Bonfim-MendonçaClinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
Fabrícia GimenesClinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
Silvia S Dantas AlczukClinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
Terezinha I Estivalet SvidzinskiMedical Mycology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil.
Márcia E Lopes ConsolaroClinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil. melconsolaro@gmail.com.ORCID http://orcid.org/0000-0001-9102-4865
Universidade Estadual de Maringá · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisAcute uncomplicated lower urinary tract infections (UTI) and vulvovaginal candidiasis (VVC) both occur frequently in women. Although VVC is believed to commonly occur after antibiotic therapy, few studies have demonstrated this association. Thus, the aim of the study was to estimate the prevalence of colonization by Candida spp. and VVC after norfloxacin (NOR) use for UTI and the effects on the vaginal microbiota and inflammatory process.

methodsThis was a prospective cohort study of women with culture-proven UTI who were treated with NOR (antibiotic group). The control group consisted of women with noninfectious diseases or in preventive care. Candida vaginal infections were monitored both clinically and mycologically at baseline and at the follow-up evaluation.

resultsAll women showed UTI remission after NOR treatment, and no woman in either group, antibiotic and control, showed symptoms of VVC. Both groups showed similar ratios of a positive Candida culture at baseline (6.7 % and 12.8 %, respectively) and at follow-up (3.3 % and 8.5 %, respectively) (p = 0.2768 and p = 0.5035, respectively). The antibiotic group showed no increased risk of Candida colonization or VVC after NOR treatment compared with the control group [odds ratio (OR) 0.556, 95 % confidence interval (CI) 0.2407-10.05].

conclusionsNOR was effective for UTI treatment, did not increase the risk of vaginal colonization by Candida or VVC, and did not lead to major disturbances of the vaginal microbiota.

Indexed as

Acute DiseaseAdolescentAdultAnti-Bacterial AgentsBrazilCandidaCandidiasis, VulvovaginalCase-Control StudiesColony Count, MicrobialFemaleHumansMicrobiotaMiddle AgedNorfloxacinPrevalenceProspective StudiesAnti-Bacterial AgentsNorfloxacinNorfloxacinTreatmentUrinary tract infectionVaginal Candida colonizationVaginal microbiotaVulvovaginal candidiasis

Identifiers

PMID26564224
OpenAlexW2294606756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.